Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Research Report, Competitive, Technology and Forecast Analysis 2025-2032
Description
Market Overview
According to DIResearch's in-depth investigation and research, the global Duchenne Muscular Dystrophy (DMD) Therapeutics market size will reach 4,044.48 Million USD in 2025 and is projected to reach 49,649.54 Million USD by 2032, with a CAGR of 43.08% (2025-2032). Notably, the China Duchenne Muscular Dystrophy (DMD) Therapeutics market has changed rapidly in the past few years. By 2025, China's market size is expected to be Million USD, representing approximately % of the global market share.
Research Summary
Duchenne Muscular Dystrophy (DMD) drugs are medications specifically developed to address the symptoms and underlying causes of DMD, a genetic disorder characterized by progressive muscle degeneration and weakness. These drugs may include corticosteroids, which can help slow muscle deterioration and delay the loss of function. Emerging treatments encompass gene therapies designed to correct or replace the faulty dystrophin gene responsible for DMD, potentially offering more targeted and transformative approaches to managing the disease. DMD drugs aim to improve muscle function, mobility, and overall quality of life for individuals affected by this condition, representing significant advancements in the medical management of DMD.
The major global suppliers of Duchenne Muscular Dystrophy (DMD) Therapeutics include Sarepta Therapeutics, PTC Therapeutics, Pfizer, Bristol-Myers Squibb, Italfarmaco, Santhera Pharmaceuticals, etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of Duchenne Muscular Dystrophy (DMD) Therapeutics. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major suppliers, as well as the market status and trends of different product types and applications in the global Duchenne Muscular Dystrophy (DMD) Therapeutics market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the Duchenne Muscular Dystrophy (DMD) Therapeutics market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Duchenne Muscular Dystrophy (DMD) Therapeutics industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Suppliers of Duchenne Muscular Dystrophy (DMD) Therapeutics Include:
Sarepta Therapeutics
PTC Therapeutics
Pfizer
Bristol-Myers Squibb
Italfarmaco
Santhera Pharmaceuticals
Duchenne Muscular Dystrophy (DMD) Therapeutics Product Segment Include:
Exondys
Emflaza
Translarna
Duchenne Muscular Dystrophy (DMD) Therapeutics Product Application Include:
Hospitals
Clinics
Home Care
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend
Chapter 2: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Industry PESTEL Analysis
Chapter 3: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Porter's Five Forces Analysis
Chapter 4: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Major Regional Market Size (Revenue) and Forecast Analysis
Chapter 5: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Competitive Analysis of Key Suppliers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 6: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Forecast Analysis by Product Type
Chapter 7: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 8: Industrial Chain Analysis, Duchenne Muscular Dystrophy (DMD) Therapeutics Different Application Market Analysis (Revenue and Forecast) and Sales Channel Analysis
Chapter 9: Research Findings and Conclusion
Chapter 10: Methodology and Data Sources
According to DIResearch's in-depth investigation and research, the global Duchenne Muscular Dystrophy (DMD) Therapeutics market size will reach 4,044.48 Million USD in 2025 and is projected to reach 49,649.54 Million USD by 2032, with a CAGR of 43.08% (2025-2032). Notably, the China Duchenne Muscular Dystrophy (DMD) Therapeutics market has changed rapidly in the past few years. By 2025, China's market size is expected to be Million USD, representing approximately % of the global market share.
Research Summary
Duchenne Muscular Dystrophy (DMD) drugs are medications specifically developed to address the symptoms and underlying causes of DMD, a genetic disorder characterized by progressive muscle degeneration and weakness. These drugs may include corticosteroids, which can help slow muscle deterioration and delay the loss of function. Emerging treatments encompass gene therapies designed to correct or replace the faulty dystrophin gene responsible for DMD, potentially offering more targeted and transformative approaches to managing the disease. DMD drugs aim to improve muscle function, mobility, and overall quality of life for individuals affected by this condition, representing significant advancements in the medical management of DMD.
The major global suppliers of Duchenne Muscular Dystrophy (DMD) Therapeutics include Sarepta Therapeutics, PTC Therapeutics, Pfizer, Bristol-Myers Squibb, Italfarmaco, Santhera Pharmaceuticals, etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of Duchenne Muscular Dystrophy (DMD) Therapeutics. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major suppliers, as well as the market status and trends of different product types and applications in the global Duchenne Muscular Dystrophy (DMD) Therapeutics market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the Duchenne Muscular Dystrophy (DMD) Therapeutics market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Duchenne Muscular Dystrophy (DMD) Therapeutics industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Suppliers of Duchenne Muscular Dystrophy (DMD) Therapeutics Include:
Sarepta Therapeutics
PTC Therapeutics
Pfizer
Bristol-Myers Squibb
Italfarmaco
Santhera Pharmaceuticals
Duchenne Muscular Dystrophy (DMD) Therapeutics Product Segment Include:
Exondys
Emflaza
Translarna
Duchenne Muscular Dystrophy (DMD) Therapeutics Product Application Include:
Hospitals
Clinics
Home Care
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend
Chapter 2: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Industry PESTEL Analysis
Chapter 3: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Porter's Five Forces Analysis
Chapter 4: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Major Regional Market Size (Revenue) and Forecast Analysis
Chapter 5: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Competitive Analysis of Key Suppliers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 6: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Forecast Analysis by Product Type
Chapter 7: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 8: Industrial Chain Analysis, Duchenne Muscular Dystrophy (DMD) Therapeutics Different Application Market Analysis (Revenue and Forecast) and Sales Channel Analysis
Chapter 9: Research Findings and Conclusion
Chapter 10: Methodology and Data Sources
Table of Contents
165 Pages
- 1 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview
- 1.1 Product Definition and Statistical Scope
- 1.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Product by Type
- 1.2.1 Exondys
- 1.2.2 Emflaza
- 1.2.3 Translarna
- 1.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Product by Application
- 1.3.1 Hospitals
- 1.3.2 Clinics
- 1.3.3 Home Care
- 1.4 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Analysis (2020-2032)
- 1.5 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Development Status and Trends
- 1.5.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Development Status Analysis
- 1.5.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Development Trends Analysis
- 2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market PESTEL Analysis
- 2.1 Political Factors Analysis
- 2.2 Economic Factors Analysis
- 2.3 Social Factors Analysis
- 2.4 Technological Factors Analysis
- 2.5 Environmental Factors Analysis
- 2.6 Legal Factors Analysis
- 3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Porter's Five Forces Analysis
- 3.1 Competitive Rivalry
- 3.2 Threat of New Entrants
- 3.3 Bargaining Power of Suppliers
- 3.4 Bargaining Power of Buyers
- 3.5 Threat of Substitutes
- 4 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Analysis by Country
- 4.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Analysis by Country: 2024 VS 2025 VS 2032
- 4.1.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Analysis by Country (2020-2025)
- 4.1.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Forecast Analysis by Country (2026-2032)
- 4.2 United States Duchenne Muscular Dystrophy (DMD) Therapeutics Market Revenue and Growth Rate (2020-2032)
- 4.3 Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Market Revenue and Growth Rate (2020-2032)
- 4.4 Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Market Revenue and Growth Rate (2020-2032)
- 4.5 China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Revenue and Growth Rate (2020-2032)
- 4.6 France Duchenne Muscular Dystrophy (DMD) Therapeutics Market Revenue and Growth Rate (2020-2032)
- 4.7 U.K. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Revenue and Growth Rate (2020-2032)
- 4.8 South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Market Revenue and Growth Rate (2020-2032)
- 4.9 Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Market Revenue and Growth Rate (2020-2032)
- 4.10 Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Market Revenue and Growth Rate (2020-2032)
- 4.11 Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Revenue and Growth Rate (2020-2032)
- 4.12 Mexico Duchenne Muscular Dystrophy (DMD) Therapeutics Market Revenue and Growth Rate (2020-2032)
- 4.13 Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Market Revenue and Growth Rate (2020-2032)
- 4.14 India Duchenne Muscular Dystrophy (DMD) Therapeutics Market Revenue and Growth Rate (2020-2032)
- 4.15 Vietnam Duchenne Muscular Dystrophy (DMD) Therapeutics Market Revenue and Growth Rate (2020-2032)
- 4.16 Thailand Duchenne Muscular Dystrophy (DMD) Therapeutics Market Revenue and Growth Rate (2020-2032)
- 4.17 South Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Revenue and Growth Rate (2020-2032)
- 5 Competition by Suppliers
- 5.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Revenue by Key Suppliers (2021-2025)
- 5.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Competitive Landscape Analysis and Market Dynamic
- 5.2.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Competitive Landscape Analysis
- 5.2.2 Global Key Suppliers Headquarter and Key Area Sales
- 5.2.3 Market Dynamic
- 6 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Analysis by Type
- 6.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Analysis by Type: 2024 VS 2025 VS 2032
- 6.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Forecast Analysis by Type (2020-2032)
- 7 Key Companies Analysis
- 7.1 Sarepta Therapeutics
- 7.1.1 Sarepta Therapeutics Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.1.2 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
- 7.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.2 PTC Therapeutics
- 7.2.1 PTC Therapeutics Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.2.2 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
- 7.2.3 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.3 Pfizer
- 7.3.1 Pfizer Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.3.2 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
- 7.3.3 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.4 Bristol-Myers Squibb
- 7.4.1 Bristol-Myers Squibb Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.4.2 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
- 7.4.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.5 Italfarmaco
- 7.5.1 Italfarmaco Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.5.2 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
- 7.5.3 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.6 Santhera Pharmaceuticals
- 7.6.1 Santhera Pharmaceuticals Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.6.2 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
- 7.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 8 Industry Chain Analysis
- 8.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Chain Analysis
- 8.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Product Downstream Application Analysis
- 8.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Growth Rate (CAGR) by Application: 2024 VS 2025 VS 2032
- 8.2.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Forecast by Application (2020-2032)
- 8.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Typical Downstream Customers
- 8.4 Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Channel Analysis
- 9 Research Findings and Conclusion
- 10 Methodology and Data Source
- 10.1 Methodology/Research Approach
- 10.2 Research Scope
- 10.3 Benchmarks and Assumptions
- 10.4 Date Source
- 10.4.1 Primary Sources
- 10.4.2 Secondary Sources
- 10.5 Data Cross Validation
- 10.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
